Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease

• US 20100299768A1
• Filed: 06/18/2008
• Published: 11/25/2010
• Est. Priority Date: 06/18/2007
• Status: Active Grant

• Current Assignee: Commissariat a L'Energie Atomique (AES Corporation)
• Original Assignee: Commissariat a L'Energie Atomique (AES Corporation)
• Inventors: Deglon, Nicole, Perrin, Valerie
• Granted Patent: US 8,217,018 B2
• Time in Patent Office: Days
• US Class Current: 800/9
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/111 spanning the whole gene, or a large part of it
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/53 partially self-complementary or closed

Abstract

Isolated double-stranded short interfering nucleic acid molecules inhibiting the expression of endogenous wild-type and exogenous human mutant huntintin genes in cells of a non-human mammal which are expressing both said huntingtin genes, and their application for the treatment of Huntington'"'"'s disease as well as to study Huntington'"'"'s disease in rodent models.

Claims

1. An isolated double-stranded short interfering nucleic acid molecule comprising complementary sense and antisense regions, wherein:

the antisense region has 15 to no more than 19 contiguous nucleotides that are complementary to a human huntingtin transcript, said nucleotides being encoded by a sequence selected from the group consisting of SEQ ID NO;

1, SEQ ID NO;

2, and SEQ ID NO;

3,

the sense and antisense regions have at least 15 contiguous nucleotides that are complementary to each other and form a duplex, and

said double-stranded short interfering nucleic acid molecule inhibits the expression of endogenous wild-type and exogenous human mutant huntingtin genes in cells of a non-human mammal which are expressing both said huntingtin genes.

2. The double-stranded short interfering nucleic acid molecule according to claim 1, wherein the sense region comprises at least 15 contiguous nucleotides that are encoded by a sequence selected from the group consisting of SEQ ID NO:

4, SEQ ID NO;

5, and SEQ ID NO;

6.

3. The double-stranded short interfering nucleic acid molecule according to claim 1, which is assembled from two separate oligonucleotides, each of 15 to about 30 nucleotides, to form a duplex structure of at least 15 base pairs.

4. The double-stranded short interfering nucleic acid molecule according to claim 1, which is assembled from a single oligonucleotide of 31 to about 50 nucleotides, to form a hairpin having a duplex structure of at least 15 base pairs and a loop structure of 4 to 10 nucleotides.

5. The double-stranded short interfering nucleic acid molecule according to claim 4, wherein the loop is encoded by SEQ ID NO:

7.

6. The double-stranded short interfering nucleic acid molecule according to claim 5 which is encoded by a sequence selected from the group consisting of SEQ ID NO:

8, SEQ ID NO;

9, and SEQ ID NO;

10.

7. The double-stranded short interfering nucleic acid molecule according to claim 1, wherein one or both 3′

end(s) comprise(s) 1 to about 3 overhanging nucleotides.

8. The double-stranded short interfering nucleic acid molecule according to claim 1, wherein both ends are blunt.

9. The double-stranded short interfering nucleic acid molecule according to claim 1, which is an RNA molecule.

10. The double-stranded short interfering nucleic acid molecule according to claim 1, which comprises one or more modified pyrimidine and/or purine nucleotides.

11. The double-stranded short interfering nucleic acid molecule according to claim 1, which comprises at least one modified internucleotidic linkage.

12. The double-stranded short interfering nucleic acid molecule according to claim 1, wherein said non-human mammal is a mouse or a rat.

13. A transcription unit comprising:

a transcription initiation region, a transcription termination region, and a nucleic acid sequence encoding at least one short interfering nucleic acid molecule according to claim 1, wherein said nucleic acid sequence is operably linked to said initiation region in a manner that allows expression and/or delivery of the short interfering nucleic acid molecule in a host cell.

14. The transcription unit according to claim 13, wherein the transcription initiation region comprises a doxycycline regulated promoter.

15. An expression vector comprising a transcription unit according to claim 13.

16. The expression vector according to claim 15, which is a replication-defective and multiply attenuated lentiviral vector.

17. A cell which is modified by a vector according to claim 16.

18. A pharmaceutical composition comprising at least one short interfering nucleic acid molecule according to claim 1 in an acceptable carrier.

19. A method for preventing or treating Huntington'"'"'s disease comprising administering the short interfering nucleic acid molecule according to claim 1 to a subject.

20. A method to study Huntington'"'"'s disease in a rodent model comprising contacting the short interfering nucleic acid molecule according to claim 1 to a cell of the rodent model.